MicroRNA‑499a (rs3746444A/G) gene variant and susceptibility to type 2 diabetes‑associated end‑stage renal disease

Fawzy,Manal S.; Al Ageeli,Essam; Al‑Qahtani,Saeed Awad; Abu Alsel,Baraah T.; Kattan,Shahad W.; Alelwani,Walla; Toraih,Eman A.

doi:10.3892/etm.2021.10985

January-2022 Volume 23 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January-2022 Volume 23 Issue 1

Full Size Image

Article Open Access

MicroRNA‑499a (rs3746444A/G) gene variant and susceptibility to type 2 diabetes‑associated end‑stage renal disease

Authors:
- Manal S. Fawzy
- Essam Al Ageeli
- Saeed Awad Al‑Qahtani
- Baraah T. Abu Alsel
- Shahad W. Kattan
- Walla Alelwani
- Eman A. Toraih
View Affiliations / Copyright

Affiliations: Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt, Department of Clinical Biochemistry (Medical Genetics), Faculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia, Department of Physiology, Faculty of Medicine, Taibah University, Al Madinah Al Munawwarah 42353, Saudi Arabia, Department of Pathology, Northern Border University, Arar 1321, Saudi Arabia, Department of Medical Laboratory, College of Applied Medical Sciences, Taibah University, Yanbu 46522, Saudi Arabia, Department of Biochemistry, Faculty of Science, University of Jeddah, Jeddah 23445, Saudi Arabia, Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112‑2632, USA

Copyright: © Fawzy et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 63
|
Published online on: November 22, 2021

https://doi.org/10.3892/etm.2021.10985
Expand metrics +

Abstract

Diabetic nephropathy (DN) is a major risk factor for end‑stage renal disease (ESRD). MicroRNAs (miRNAs/miRs) and their variants may be implicated in health and disease, including DN. The present study aimed to investigate the association of the miRNA‑499a gene (MIR499A) A/G seed region variant (rs3746444) with DN‑associated ESRD susceptibility in patients with diabetes mellitus, and to determine whether there was an association between the different genotypes and the patients' laboratory and clinical data. A case‑control pilot study was conducted on 180 adult patients with type 2 diabetes mellitus. A total of 90 patients with ESRD on regular hemodialysis were considered as the cases, and 90 age‑, sex‑ and ethnicity‑matched diabetic patients with normo‑albuminuria were considered as the controls. MIR499A genotyping was performed using a TaqMan Real‑Time allele discrimination assay. Results demonstrated that the MIR499A rs3746444*G variant conferred susceptibility to the development of ESRD under co‑dominant [(odds ratio (95% confidence interval): 2.49 (1.41‑3.89) and 2.41 (1.61‑6.68) for heterozygous and homozygous comparison, respectively], dominant [2.30 (1.18‑3.90)] and allelic [1.82 (1.17‑2.83)] models. Different genotypes of the specified variant did not exhibit significant associations with the clinic‑laboratory data of the studied patients or the circulating miR‑499a plasma levels. In conclusion, results of the present study suggested that MIR499A rs3746444 may be a susceptibility variant for DN‑associated ESRD in the study population. However, larger sample size studies with different ethnicities are warranted to verify these findings.

View Figures

View References

1	Sattar A, Argyropoulos C, Weissfeld L, Younas N, Fried L, Kellum JA and Unruh M: All-cause and cause-specific mortality associated with diabetes in prevalent hemodialysis patients. BMC Nephrol. 13(130)2012.PubMed/NCBI View Article : Google Scholar
2	Al-Sayyari AA and Shaheen FA: End stage chronic kidney disease in Saudi Arabia. A rapidly changing scene. Saudi Med J. 32:339–346. 2011.PubMed/NCBI
3	Mooyaart AL: Genetic associations in diabetic nephropathy. Clin Exp Nephrol. 18:197–200. 2014.PubMed/NCBI View Article : Google Scholar
4	Lu Z, Liu N and Wang F: Epigenetic regulations in diabetic nephropathy. J Diabetes Res. 2017(7805058)2017.PubMed/NCBI View Article : Google Scholar
5	Schena FP, Serino G and Sallustio F: MicroRNAs in kidney diseases: New promising biomarkers for diagnosis and monitoring. Nephrol Dial Transplant. 29:755–763. 2014.PubMed/NCBI View Article : Google Scholar
6	Felekkis K, Touvana E, Stefanou Ch and Deltas C: MicroRNAs: A newly described class of encoded molecules that play a role in health and disease. Hippokratia. 14:236–240. 2010.PubMed/NCBI
7	Mashayekhi S, Saeidi Saedi H, Salehi Z, Soltanipour S and Mirzajani E: Effects of miR-27a, miR-196a2, and miR-146a polymorphisms on the risk of breast cancer. Br J Biomed Sci. 75:76–81. 2018.PubMed/NCBI View Article : Google Scholar
8	Toraih EA, Hussein MH, Al Ageeli E, Riad E, AbdAllah NB, Helal GM and Fawzy MS: Structure and functional impact of seed region variant in MIR-499 gene family in bronchial asthma. Respir Res. 18(169)2017.PubMed/NCBI View Article : Google Scholar
9	Fawzy MS, Toraih EA, Hamed EO, Hussein MH and Ismail HM: Association of MIR-499a expression and seed region variant (rs3746444) with cardiovascular disease in Egyptian patients. Acta Cardiol. 73:131–140. 2018.PubMed/NCBI View Article : Google Scholar
10	Wang WJ, Cai GY and Chen XM: Cellular senescence, senescence-associated secretory phenotype, and chronic kidney disease. Oncotarget. 8:64520–64533. 2017.PubMed/NCBI View Article : Google Scholar
11	Sluijter JP, van Mil A, van Vliet P, Metz CH, Liu J, Doevendans PA and Goumans MJ: MicroRNA-1 and -499 regulate differentiation and proliferation in human-derived cardiomyocyte progenitor cells. Arterioscler Thromb Vasc Biol. 30:859–868. 2010.PubMed/NCBI View Article : Google Scholar
12	Ling TY, Wang XL, Chai Q, Lau TW, Koestler CM, Park SJ, Daly RC, Greason KL, Jen J, Wu LQ, et al: Regulation of the SK3 channel by microRNA-499-potential role in atrial fibrillation. Heart Rhythm. 10:1001–1009. 2013.PubMed/NCBI View Article : Google Scholar
13	Xu Z, Han Y, Liu J, Jiang F, Hu H, Wang Y, Liu Q, Gong Y and Li X: MiR-135b-5p and MiR-499a-3p promote cell proliferation and migration in atherosclerosis by directly targeting MEF2C. Sci Rep. 5(12276)2015.PubMed/NCBI View Article : Google Scholar
14	Gene Ontology Consortium. The Gene Ontology resource: Enriching a GOld mine. Nucleic Acids Res. 49:D325–D334. 2021.PubMed/NCBI View Article : Google Scholar
15	Wang L, Zhang N, Pan HP, Wang Z and Cao ZY: MiR-499-5p contributes to hepatic insulin resistance by suppressing PTEN. Cell Physiol Biochem. 36:2357–2365. 2015.PubMed/NCBI View Article : Google Scholar
16	Toraih EA, Ismail NM, Toraih AA, Hussein MH and Fawzy MS: Precursor miR-499a Variant but not miR-196a2 is associated with rheumatoid arthritis susceptibility in an Egyptian population. Mol Diagn Ther. 20:279–295. 2016.PubMed/NCBI View Article : Google Scholar
17	Toraih EA, Fawz MS, Elgazzaz MG, Hussein MH, Shehata RH and Daoud HG: Combined genotype analyses of precursor miRNA196a2 and 499a variants with hepatic and renal cancer susceptibility a preliminary study. Asian Pac J Cancer Prev. 17:3369–3375. 2016.PubMed/NCBI
18	Fawzy MS, Abu AlSel BT, Al Ageeli E, Al-Qahtani SA, Abdel-Daim MM and Toraih EA: Long non-coding RNA MALAT1 and microRNA-499a expression profiles in diabetic ESRD patients undergoing dialysis: A preliminary cross-sectional analysis. Arch Physiol Biochem. 126:172–182. 2020.PubMed/NCBI View Article : Google Scholar
19	Ghani AA, Al Waheeb S, Al Sahow A and Hussain N: Renal biopsy in patients with type 2 diabetes mellitus: Indications and nature of the lesions. Ann Saudi Med. 29:450–453. 2009.PubMed/NCBI View Article : Google Scholar
20	Nah EH, Cho S, Kim S and Cho HI: Comparison of urine albumin-to-creatinine ratio (ACR) between ACR strip test and quantitative test in prediabetes and diabetes. Ann Lab Med. 37:28–33. 2017.PubMed/NCBI View Article : Google Scholar
21	Fawzy MS and Beladi FIA: Association of circulating vitamin D, VDBP, and vitamin D receptor expression with severity of diabetic nephropathy in a group of saudi type 2 diabetes mellitus patients. Clin Lab. 64:1623–1633. 2018.PubMed/NCBI View Article : Google Scholar
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
23	Shastry BS: SNPs: Impact on gene function and phenotype. Methods Mol Biol. 578:3–22. 2009.PubMed/NCBI View Article : Google Scholar
24	Hoffman AE, Zheng T, Yi C, Leaderer D, Weidhaas J, Slack F, Zhang Y, Paranjape T and Zhu Y: MicroRNA miR-196a-2 and breast cancer: A genetic and epigenetic association study and functional analysis. Cancer Res. 69:5970–5977. 2009.PubMed/NCBI View Article : Google Scholar
25	Misra MK, Pandey SK, Kapoor R, Sharma RK and Agrawal S: Genetic variants of MicroRNA-related genes in susceptibility and prognosis of end-stage renal disease and renal allograft outcome among north Indians. Pharmacogenet Genomics. 24:442–450. 2014.PubMed/NCBI View Article : Google Scholar
26	Kato M, Yuan H, Xu ZG, Lanting L, Li SL, Wang M, Hu MC, Reddy MA and Natarajan R: Role of the Akt/FoxO3a Pathway in TGF-beta1-mediated mesangial cell dysfunction: A novel mechanism related to diabetic kidney disease. J Am Soc Nephrol. 17:3325–3335. 2006.PubMed/NCBI View Article : Google Scholar
27	Qin G, Zhou Y, Guo F, Ren L, Wu L, Zhang Y, Ma X and Wang Q: Overexpression of the FoxO1 ameliorates mesangial cell dysfunction in male diabetic rats. Mol Endocrinol. 29:1080–1091. 2015.PubMed/NCBI View Article : Google Scholar
28	Chang AS, Hathaway CK, Smithies O and Kakoki M: Transforming growth factor-β1 and diabetic nephropathy. Am J Physiol Renal Physiol. 310:F689–F696. 2016.PubMed/NCBI View Article : Google Scholar
29	Akhtar S, Yousif MH, Dhaunsi GS, Sarkhouh F, Chandrasekhar B, Attur S and Benter IF: Activation of ErbB2 and downstream signalling via Rho kinases and ERK1/2 contributes to diabetes-induced vascular dysfunction. PLoS One. 8(e67813)2013.PubMed/NCBI View Article : Google Scholar
30	Omote K, Gohda T, Murakoshi M, Sasaki Y, Kazuno S, Fujimura T, Ishizaka M, Sonoda Y and Tomino Y: Role of the TNF pathway in the progression of diabetic nephropathy in KK-A(y) mice. Am J Physiol Renal Physiol. 306:F1335–F1347. 2014.PubMed/NCBI View Article : Google Scholar
31	Al-Lamki RS and Mayadas TN: TNF receptors: Signaling pathways and contribution to renal dysfunction. Kidney Int. 87:281–296. 2015.PubMed/NCBI View Article : Google Scholar
32	Gödel M, Hartleben B, Herbach N, Liu S, Zschiedrich S, Lu S, Debreczeni-Mór A, Lindenmeyer MT, Rastaldi MP, Hartleben G, et al: Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest. 121:2197–2209. 2011.PubMed/NCBI View Article : Google Scholar
33	Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA and Sharma K: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti transforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA. 97:8015–8020. 2000.PubMed/NCBI View Article : Google Scholar
34	Mori H, Inoki K, Masutani K, Wakabayashi Y, Komai K, Nakagawa R, Guan KL and Yoshimura A: The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem Biophys Res Commun. 384:471–475. 2009.PubMed/NCBI View Article : Google Scholar
35	Ciccacci C, Latini A, Greco C, Politi C, D'Amato C, Lauro D, Novelli G, Borgiani P and Spallone V: Association between a MIR499A polymorphism and diabetic neuropathy in type 2 diabetes. J Diabetes Complications. 32:11–17. 2018.PubMed/NCBI View Article : Google Scholar
36	Forbes JM and Thorburn DR: Mitochondrial dysfunction in diabetic kidney disease. Nat Rev Nephrol. 14:291–312. 2018.PubMed/NCBI View Article : Google Scholar
37	Flemming NB, Gallo LA and Forbes JM: Mitochondrial dysfunction and signaling in diabetic kidney disease: Oxidative stress and beyond. Semin Nephrol. 38:101–110. 2018.PubMed/NCBI View Article : Google Scholar